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ABSTRACT
Objective: To investigate the cost-utility of eprosartan versus enalapril
(primary prevention) and versus nitrendipine (secondary prevention) on
the basis of head-to-head evidence from randomized controlled trials.
Methods: The HEALTH model (Health Economic Assessment of Life
with Teveten® for Hypertension) is an object-oriented probabilistic Monte
Carlo simulation model. It combines a Framingham-based risk calculation
with a systolic blood pressure approach to estimate the relative risk
reduction of cardiovascular and cerebrovascular events based on recent
meta-analyses. In secondary prevention, an additional risk reduction is
modeled for eprosartan according to the results of the MOSES study
(“Morbidity and Mortality after Stroke—Eprosartan Compared to
Nitrendipine for Secondary Prevention”). Costs and utilities were derived
from published estimates considering European country-speciﬁc health-
care payer perspectives.
Results: Comparing eprosartan to enalapril in a primary prevention
setting the mean costs per quality adjusted life year (QALY) gained were
highest in Germany (€24,036) followed by Belgium (€17,863), the UK
(€16,364), Norway (€ 13,834), Sweden (€ 11,691) and Spain (€ 7918). In
a secondary prevention setting (eprosartan vs. nitrendipine) the highest
costs per QALY gained have been observed in Germany (€9136) followed
by the UK (€6008), Norway (€1695), Sweden (€907), Spain (€-2054) and
Belgium (€-5767).
Conclusions: Considering a €30,000 willingness-to-pay threshold per
QALY gained, eprosartan is cost-effective as compared to enalapril in
primary prevention (patients 50 years old and a systolic blood pressure
160 mm Hg) and cost-effective as compared to nitrendipine in second-
ary prevention (all investigated patients).
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Introduction
According to the World Health Organization, approximately
62% of cerebrovascular disease and 49% of ischemic heart
disease are attributable to suboptimal blood pressure control.
Worldwide, high blood pressure is estimated to cause 7.1 million
deaths per year (i.e., 13% overall mortality) [1].
High blood pressure in nondiabetics is deﬁned as a diastolic
blood pressure (DBP) >90 mm Hg and/or a systolic blood
pressure (SBP) >140 mm Hg and graded into mild (SBP 140–
159 and/or DBP 90–99 mm Hg), moderate (160–179 and/or
100–109 mm Hg) and severe hypertension (180 and/or
110 mm Hg) [2].
The effectiveness of antihypertensive drug treatment is well
established and has been quantiﬁed in terms of overall reduction
in the relative risk for cerebrovascular events (such as stroke
and transient ischemic attack) and cardiovascular diseases (such
as myocardial infarction [MI] and angina pectoris [AP]) [3–9].
In patients with moderate to severe hypertension, without
cardiovascular or cerebrovascular diseases (primary prevention
population), there is evidence that the angiotensin receptor
blocker (ARB) eprosartan (Teveten, Tevetens, Barcelona, Spain) is
more effective in lowering SBP as directly compared to the
angiotensin-converting-enzyme inhibitor (ACEI) enalapril [10].
During the past 10 years, several prospective cohort studies and
meta-analyses have documented that SBP is a more important risk
factor for cardiovascular (CV) and cerebrovascular (CBV) dis-
eases than DBP, as was believed in the past [6,7,11–14].
In the ﬁeld of secondary prevention the PROGRESS study
(Perindopril Protection Against Recurrent Stroke Study) was the
ﬁrst large trial to document the positive inﬂuence of hypertension
treatment on the CV and CBV risk within a population of
patients with a primary CBV event. In this study, the ACEI
perindopril (in possible combination with the diuretic indapam-
ide) was compared to a placebo [15].
Further evidence for the reduction of CV and CBV events
within a population of patients with previous CBV events (stroke
and/ or transient ischemic attack [TIA]) was provided by
the MOSES study (MOrbidity and mortality after Stroke—
Eprosartan vs. nitrendipine for Secondary prevention). In this
secondary prevention study, the calcium channel blocker (nitren-
dipine) was compared to the ARB eprosartan [16]. Although the
blood pressure reduction in both study arms was comparable (as
intended by the study protocol) eprosartan showed a signiﬁcantly
greater relative risk reduction for CV and CBV events and overall
mortality compared to that of the patients treated with nitren-
dipine. It is likely that this effect is attributable to greater stimu-
lation of the angiotensin II receptor and improved endothelial
function (both not measured in MOSES) in patients on ARB
therapy [17].
As both comparator substances, enalapril and nitrendipine,
are available as generics depending on the country, there is a
sizeable price difference between them and eprosartan. This
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poses the question of whether the improved ability to lower SBP
with eprosartan in primary prevention, as well as the risk reduc-
tion in secondary prevention, translates into sufﬁcient health
gains in quality adjusted life years (QALYs) to justify the higher
cost.
Methods
The HEALTH (Health Economic Assessment of Life with
Teveten for Hypertension) model is an object-oriented probabi-
listic Monte Carlo simulation model based on a Markov process
with ﬁrst- and second-order calculations [18]. The model was
developed using Delphi and C++ for the operating systems
Windows 98, ME, 2000, and XP. The Borland Delphi develop-
ment environment was used as the primary programming tool.
Markov Health States
The main Markov health states simulated by the model are “CV
& CBV naive” (starting stage for the primary prevention popu-
lation), “CV events,” “CBV events” (starting stage for the sec-
ondary prevention population), and “Death.” The “CV event”
state is further classiﬁed in MI, AP, and other CV events and the
“CBV event” state is further classiﬁed in stroke, TIA, and other
CBV events. A simpliﬁed structure of the Markov approach is
shown in Figure 1.
Health State Transition
The health-state transitions are calculated in a stepwise proce-
dure and depend on the patient’s CV and CBV risk proﬁle and on
the therapy effect. First, a base risk for CV and CBV events is
calculated and combined with a relative risk reduction based on
the SBP reduction. In the secondary prevention analysis, an addi-
tional risk reduction beyond blood pressure reduction is applied,
based on the outcomes of the MOSES trial. These simulations
steps are described in detail in the following including the mor-
tality predictions and the randomization procedure used within
the model.
Base risk assessment. The Framingham algorithms, which are
published in detail elsewhere [19,20], were used to predict the
base risk of speciﬁc CV and CBV events. For the prediction of CV
events, the risk equation published by D’Agostino et al. was used
[19]. The cardiovascular events included in the model were AP
and MI. The risk equation published by Wolf et al. was used to
predict the risk of the CBV events stroke and TIA [20]. Because
of the fact that the Framingham risk equations cover several CV
and CBV events, additional groups named “other CV events”
and “other CBV events” were included in the model to account
coronary insufﬁciency, intracerebral hemorrhage, and subarach-
noid hemorrage.
For predicting the base risks in a population with previous
CBV events (secondary prevention population), the Framingham
algorithms were adjusted using the outcomes of the MOSES
study [16]. The rationale for adjusting the Framingham algo-
rithms was the greater power of the MOSES study in patients
with previous CBV events and concomitant hypertension. In
contrast to the Framingham population that included 216
patients with previous CBV events and concomitant hyperten-
sion [21], the MOSES study included 1352 patients.
Risk reduction related to the systolic blood pressure reduction.
To estimate the effect of antihypertensive therapy on the risk
reduction of CV and CBV outcomes, a systematic literature
search was conducted.
The literature review revealed a meta-analysis conducted by
the Blood Pressure Lowering Treatment Trialists’ Collaboration
which provided all the necessary data on SBP-related risk reduc-
tion for a primary prevention population [7]. This meta-analysis
by Turnbull et al. summarized data from 29 randomized con-
trolled trials including a total of 162,341 patients. The duration
of follow-up ranged from 2.0 to 8.4 years with a mean duration
of around 5 years. This study concluded that the weighted mean
SBP differences between randomized groups seemed to be
directly associated with differences in risk of CV and CBV events.
By contrast, differences in blood pressure were not associated
with the risk of heart failure. Therefore, the HEALTH model
focused on CV diseases (including MI and AP) and CBV diseases
(including stroke and transient ischemic attack) as the primary
clinical outcomes. On the basis of the combined data of all drug
regimen comparisons provided in the meta-analysis, a regression
analysis was performed to determine the connection between the
relative risk reduction of CV and CBV events and systolic blood
pressure reduction (SBPR). In both cases, an exponential func-
tion was the best estimate with an R2 of 0.812 and a P-value of
0.002 for CV events [EXP (0.02886 ¥ SBPR in mmHg [e.g.,
-10 mm Hg])] and a R2 of 0.927 and a P-value of 0.0001 in
for CBV events [EXP (0.06258 ¥ SBPR in mmHg [e.g.,
-10 mm Hg])], respectively.
The relative risk reduction of CBV events for patients with a
previous CBV event was calculated via the same methodology
previously described based on data from a meta-analysis by
Rashid et al. [6]. Also in this case, an exponential function was
the best estimate with an R2 of 0.872 and a P-value of 0.002
[EXP (0.03716 ¥ SBPR in mmHg [e.g., -10])].
As data on the impact of lowering SBP on the secondary
prevention of CV events (CV event risk in patients with a previ-
ous CV event) are scarce, the model assumed two extreme sce-
narios: the relative risk reduction for CV events would be 1) zero
(worst scenario); or 2) equivalent to that calculated in the
primary prevention regression analysis (best scenario). For the
base case scenario, it is assumed that the relative risk reduction
based on SBP is 50% of the reduction observed in primary
prevention trials. Sensitivity analyses were employed to test the
inﬂuence of the extreme cases (no risk reduction or the same risk
reduction as in the primary prevention trials).
Risk reduction beyond blood pressure reduction. In the second-
ary prevention observation using the HEALTH model, an addi-Figure 1 Simpliﬁed structure of the Markov approach.
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tional risk reduction beyond blood pressure reduction was
modeled for patients with previous CBV events. These additional
risk reductions of 25% for CV and of 25% for CBV events were
applied to the eprosartan arm only on the basis of the results of
the MOSES study [16].
Mortality. The probability of death after speciﬁc CV and CBV
events was evaluated using the death rate prediction of the
Framingham heart study published by Cupples et al. [22]. The
general probability of death was estimated on the basis of
country-speciﬁc life tables retrieved from the WHO website [23].
For the secondary prevention simulations, two different mor-
tality settings were analyzed. In the base case setting, the prob-
ability of death was calculated on the basis of the Framingham
mortality algorithms. In the sensitivity analyses, the mortality
investigated in the MOSES study was simulated. This probability
of death was lower than the probability predicted by the
Framingham algorithms. The mean 1-year period from the occur-
rence of the CBV to the patient’s recruitment in the MOSES
study was identiﬁed as the main reason for this difference because
mortality (especially mortality because of stroke) is highest in the
ﬁrst year after the event, according to published studies [24,25].
Hence, compared to a real-world scenario, the mortality
observed in the MOSES study might have been underestimated
because of the fact that some patients had already died during the
1-year period between the qualifying event and inclusion in the
study.
Randomization and simulation. For the simulation of the occur-
rence of an event or mortality, the model used combined multiple
recursive 64-bit random number generators to produce a
uniformly distributed integer between 0 and 2377 with a
periodicity = 3.0783e+113 [26]. Each patient had an individual
random number generator enabling the simulation of events and
mortality independent from other patients. Thus, each patient
was regarded as an individual, to gain the best possible approxi-
mation to a real world scenario.
For the simulation of the occurrence of an event, a random
number was drawn at each time step. If the random number was
less than or equal to the transition probability for the current
health state or parameter change, transition to the next health
state occurred.
Time Horizon
A lifelong perspective was used. Therefore, the model discrimi-
nates between a treatment time horizon and a lifelong follow-up
period.
The treatment time horizon used in the primary prevention
base case analysis was set to 5 years based on the meta-analysis
by Turnbull et al. that provided all necessary data concerning the
CV and CBV event risk reduction. This treatment time horizon
was varied in sensitivity analyses.
In the ﬁeld of secondary prevention, a treatment time horizon
of 2.5 years was selected based on the mean treatment period
within the MOSES study.
For modeling the treatment follow-up effects after the treat-
ment time horizon, it was assumed that treatment was stopped in
all patients, thus neither treatment costs (drug and monitoring
costs) nor treatment effects (blood pressure reduction; effect
beyond blood pressure reduction) were simulated after the treat-
ment time horizon.
SBP Reduction
In the ﬁeld of primary prevention, a study by Sega et al. [10]
was used as the basis for the SBPR of eprosartan and enalapril.
This study compared the efﬁcacy of eprosartan (n = 59) to
that of enalapril (n = 59) in patients with moderate to severe
hypertension. Sega et al. found a signiﬁcant difference
(P = 0.025) in SBP at the study end point when comparing
the eprosartan (-29.1  2.9 mm Hg) group to the enalapril
(-21.1  2.7 mm Hg) group.
In the case of secondary prevention for drugs, nitrendipine
and eprosartan, the same blood pressure reduction was applied
based on the results of the MOSES study. Because of the fact that
the blood pressure reduction in MOSES was comparable
between the nitrendipine and eprosartan arm, the mean systolic
blood pressure reduction of 15.99 mmHg relating to the 671
patients of the Nitrendipine arm was taken into account [16].
This procedure is based on the fact that the adjustment of the
Framingham algorithms to the MOSES outcomes was based on
the Nitrendipine arm, where no risk reduction beyond blood
pressure reduction was observed.
In the case of compliance to treatment, the blood pressure
reduction of the RCTs was taken into account for each treatment
strategy. In the case of noncompliance, the systolic blood pres-
sure reduction was set to zero.
Patient Compliance
As the HEALTH model has a 5-year base case treatment time
horizon for the primary prevention simulations and a 2.5-year
treatment time horizon for the secondary prevention simulations,
data from the Conlin et al. study were used to estimate persis-
tence data over 5 years of drug treatment [27]. This study inves-
tigated the persistence pattern of a large, geographically diverse,
drug-insured population of 15,175 patients over a 4-year period.
According to this study, switch rates were comparable for all
drug classes, except for thiazide diuretics, which showed a higher
switch rate.
Because of the fact that the model investigates the efﬁcacy of
an ARB versus speciﬁc comparators and because it is not known
to which drugs patients in these regimes would switch, switching
has not been taken into account. The model differentiates
between compliance and noncompliance only. Conlin and col-
leagues report 12-month persistence on ACEI of 60.7%, exclud-
ing a 9.6% switch rate. The following calculation was made to
adjust for switching; (60.7% ¥ 1)  (1 - 9.6%) = 67.2%.
Thus, the compliance rates used for the primary prevention
simulations in the model were: ARB 73.3% and 60.9% after the
ﬁrst and fourth years, respectively; ACEI 67.2% and 57.3% after
the ﬁrst and fourth years, respectively. Data on partial compliance
(e.g., irregular drug use) for the drug classes ARB and ACEI were
not identiﬁed; hence, this aspect was not included in the model.
Published compliance data for a secondary prevention (high-
risk patients with previous CBV events and concomitant hyper-
tension) population are very limited. According to one German
study, the overall compliance rate for antihypertensive treatment
1 year after the stroke event was 90.8% [28]. Compared to the
compliance rates within a primary prevention population after 1
year (ARB 73.3%, ACEI 67.2%, CCB 60.0%, and diuretics
48.6%) [27], this overall compliance rate (90.8%) was greater in
the high-risk patients with previous stroke.
As a result of this difference, it seems to be impossible to deﬁne
adequate compliance rates in the ﬁeld of secondary prevention
without applying major assumptions. Therefore, the analyses in
the ﬁeld of secondary prevention were performed without consid-
ering patient compliance (compliance was set to 100%).
Discounting
Future costs and health effects were discounted according to
country-speciﬁc guidelines for health economic evaluations. The
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discount rates for health effects and costs used are shown in
Table 1.
Willingness-to-Pay Threshold per QALY Gained
In the United Kingdom, the cost per QALY gained threshold
assessed to be cost-effective is £20,000 [ª €30,000], although
recent reimbursement decisions made by the National Institute
for Health and Clinical Excellence show that the upper limit is
moving toward a cutoff point of £30,000 (ª €45,000) [35].
The Swedish National Board of Health and Welfare discrimi-
nates between low (<SEK 100,000), moderate (SEK 100,000 to
500,000), high (SEK 500,000 to 1,000,000) and very high costs
(>SEK 1,000,000) per QALY gained [36]. According to experi-
enced health economists, costs per QALY gained within the low
and moderate range are usually regarded as cost-effective
[37,38], leading to a threshold of SEK 500,000 (ª €54,000) per
QALY gained.
In Germany, the Institute for Quality and Efﬁciency in Health
Care (IQWiG) gave an upper limit for the cost per QALY thresh-
old of €50,000 in their ﬁrst version method article [39]. Never-
theless, in newer method articles, the QALY method is put into
question in general and no further statement on this threshold is
given.
In all other countries investigated (Belgium, Spain, and
Norway), there is no ofﬁcial information on the willingness to
pay threshold per QALY gained.
To make the country results comparable to each other we
generally applied the lower UK willingness to pay threshold of
€30,000 as the cutoff value for cost-effectiveness, independent of
possibly higher QALY thresholds in individual countries.
Input Data
Population Characteristics
To calculate the risk for CV and CBV events, speciﬁc population
characteristics were used to apply the Framingham algorithms.
For the primary prevention population (patients without any
CV or CBV event at baseline), country-speciﬁc population char-
acteristics for hypertensive patients have been derived on the
basis of published literature and/or by analyses of population
health surveys. The population input data for the primary pre-
vention simulations is shown in Table 2 for Belgium, Germany,
and Norway and in Table 3 for Spain, Sweden and the United
Kingdom.
For the secondary prevention population, the patient charac-
teristics of the MOSES study population were applied for each
country. The rationale for this procedure was the fact that
country-speciﬁc data for this highly selective patient cohort
(hypertensive patients with a previous CBV event) have not been
identiﬁed. The population input parameters for the secondary
prevention simulations are shown in Table 4.
Health UtilityWeights
According to the health states achieved during the simulation
process, different utilities were applied to each patient modeled
based on published literature. Each patient started with a health
utility value based on a typical hypertensive patient depending on
sex and mean age. During the simulation process, the utility was
reduced by an event-speciﬁc utility reduction factor if a speciﬁc
CV or CBV event developed in the patient. If the patient died
because of an event or because of other reasons, the health utility
was set to zero.
The utility values applied to the model were based on a
Swedish study [60]. In this study, data from the 1996–1997
Survey of Living Conditions (ULF), a cross-sectional study based
on personal interviews with a representative sample (n = 11,698,
aged 16–84) of the Swedish population were used. The health
utility was evaluated by the EQ-5D self-classiﬁer. The cohort
included 869 patients with hypertension, 520 with ischemic heart
disease and 86 with stroke.
Within the HEALTH model, the same utility values were
applied for MI and AP (ICD-9 410–414) as well as for stroke and
TIA (ICD-9 430–438) because of the fact that the population-
Table 1 Country-speciﬁc discount rates used in the HEALTH model
Country
Discount rate
ReferenceHealth effects Costs
Belgium 3.5% 3.5% [29]
Germany 5.0% 5.0% [30]
Norway 4.0% 4.0% [31]
Spain 3.5% 3.5% [32]
Sweden 3.0% 3.0% [33]
United Kingdom 3.5% 3.5% [34]
Table 2 Population characteristics—primary prevention setting (Belgium, Germany, and Norway)
Parameter
Belgium* Germany Norway†
Males Females Ref. Males Females Ref. Males Females Ref.
Proportion (males/females) 48% 52% [40]‡ 48% 52% [40]‡ 44% 56% [41]
Age in years 57.3 (12.0) 60.6 (11.3) [40]‡ 57.3 (12.0) 60.6 (11.3) [40]‡ 64.3 (11.3) 66.7 (11.3) [42]
Baseline SBP in mm Hg¶ 179.2 (2.3) 179.2 (2.3) [10] 179.2 (2.3) 179.2 (2.3) [10] 179.2 (2.3) 179.2 (2.3) [10]
Baseline DBP in mm Hg¶ 116.8 (0.5) 116.8 (0.5) [10] 116.8 (0.5) 116.8 (0.5) [10] 116.8 (0.5) 116.8 (0.5) [10]
Patients with diabetes 12.1% 13.4% [40]‡ 12.1% 13.4% [40]‡ 11.4% 12.0% [41]
Current smoker 24.4% 12.6% [40]‡ 24.4% 12.6% [40]‡ 20.4% 15.4% [42]
Left ventricular hypertrophy 17.5% 18.5% [43] 17.5% 18.5% [43] 14% 9% [44–46]
Atrial ﬁbrillation 1.6% 1.4% [47] 1.6% 1.4% [47] 3.1% 2.8% [48]
Total cholesterol in mg/dl 247.2 (47.3) 257.3 (44.7) [40]‡ 247.2 (47.3) 257.3 (44.7) [40]‡ 239.4 (42.5) 258.7 (50.2) [42]
HDL-cholesterol in mg/dl 49.6 (15.2) 62.4 (17.8) [40]‡ 49.6 (15.2) 62.4 (17.8) [40]‡ 46.3 (15.4) 54.1 (15.4) [42]
Mean age at menopause# — 52.0 [49] — 52.0 [49] — 49.0 [50]
Alcohol consumption** — 31.0% [40]‡ — 31.0% [40]‡ — 65.3% [51]
*Because of the fact that published literature lacks Belgian population characteristics, German data was applied.
†In cases where Norwegian data were not identiﬁed Swedish data were used as proxy.
‡Data are based on our own analysis of the German Federal health survey 1998.
¶Baseline blood pressure data was based on the Sega et al. study.
#During the simulation the mean age of menopause was used to simulate whether a female patient had already entered menopause.
**According to the Framingham algorithms moderate alcohol consumption has only a preventive effect in females.
SBP, systolic blood pressure; DBP, diastolic blood pressure
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based Swedish study on health utility weights used this combined
disease classiﬁcation.
In view of the fact that additionally a secondary prevention
population was simulated, a differentiation between a utility
reduction for the ﬁrst event and a utility reduction for the sub-
sequent events was made.
By reviewing data from an overview of preference weights, a
general convention was identiﬁed. According to the overview of
published health utilities, the utility reduction for subsequent CV
and CBV events is half of the utility reduction of the primary
event [61].
The health utility weights used in the model are shown in
Table 5. To calculate a population’s baseline utility value, the
basis utility was adapted by the age-speciﬁc utility summand
using the population’s mean age at baseline and reduced by the
utility reduction for hypertension. An age-related utility adapta-
tion during the simulation process was not applied, thus sensitive
analyses, simulating the lowest possible age-related baseline
utility (basis utility minus utility reduction for hyperten-
sion; males = 0.685; females = 0.6443) and the highest possible
age-related baseline utility (basis utility - utility reduction
hypertension + x for 20–29-year-old subjects; males = 0.9052;
females = 0.8645) were applied.
Additionally, a 10% variation of the baseline utility and the
disutilities has been simulated to investigate possible country-
speciﬁc variations of the EQ-5D health utility weights.
Cost Data
An overview of the therapy costs and of the cardiovascular
and cerebrovascular event costs used in the model is given in
Table 6.
Drug costs are based on deﬁned daily doses (DDD) of each
medication; hence, the costs of 600 mg eprosartan, 10 mg enala-
pril, and 20 mg nitrendipine were used in the model. Nitren-
dipine is not licensed in Norway, Sweden, and the UK. In this
case, the costs of another frequently used calcium channel
blocker, amlodipine 5 mg, were applied. The drug costs are based
on an average price calculated over the DDD of all reimbursed
products of the same substance within a country.
Table 3 Population characteristics—primary prevention setting (Spain, Sweden, and the UK)
Parameter
Spain Sweden UK
Males Females Ref. Males Females Ref. Males Females Ref.
Proportion (males/females) 43% 57% [52] 44% 56% [53] 46% 54% [54]*
Age in years 67.0 (7.9) 68.2 (8.2) [52] 65.4 (11.2) 66.9 (11.7) [53] 64.8 (12.3) 67.2 (12.6) [54]*
SBP in mm Hg† 179.2 (2.3) 179.2 (2.3) [10] 179.2 (2.3) 179.2 (2.3) [10] 179.2 (2.3) 179.2 (2.3) [10]
DBP in mm Hg† 116.8 (0.5) 116.8 (0.5) [10] 116.8 (0.5) 116.8 (0.5) [10] 116.8 (0.5) 116.8 (0.5) [10]
Patients with diabetes 31.0% 30.0% [52] 26.3% 19.2% [53] 14.6% 10.8% [54]*
Current smoker 30.7% 6.5% [52] 15.0% 10.6% [53] 13.7% 14.7% [54]*
Left ventricular hypertrophy 23.4% 17.8% [52] 14% 9% [44] 10.2% 6.2% [54]*
Atrial ﬁbrillation 7.9% 8.0% [52] 3.1% 2.8% [48] 4.5% 3.7% [54]*
Total cholesterol in mg/dl 219.2 (37.5) 219.2 (37.5) [52] 222.9 (41.5) 244.8 (47.0) [55] 211.8 (44.2) 235.3 (47.0) [54]*
HDL-cholesterol in mg/dl 56.4 (20.9) 56.4 (20.9) [52] 38.2 (9.2) 44.6 (9.8) [55] 51.8 (14.3) 61.9 (15.6) [54]*
Mean age at menopause‡ — 50.0 [56] — 51.3 [57] — 51.0 [54]*
Alcohol consumption§ — 20.0% [58] — 65.3% [51] — 58.7% [54]*
*Data are based on our own analysis of the England health survey 2003.
†Baseline blood pressure data was based on the Sega et al. study.
‡During the simulation the mean age of menopause was used in order simulate whether a female patient had already entered menopause.
§According to the Framingham algorithms moderate alcohol consumption has only a preventive effect in females.
SBP, systolic blood pressure; DBP, diastolic blood pressure.
Table 4 Population characteristics—secondary prevention setting
Parameter Males Females Ref.
Proportion (males/females) 54.8% 45.2% [16]*
Age in years 66.96 (8.82)* 70.49 (9.9)* [16]*
SBP in mm Hg 152.47 (18.66) 151.49 (17.71) [16]*
DBP in mm Hg 87.83 (9.38) 86.44 (9.77) [16]*
Patients with diabetes 39.1% 36.0% [16]*
Current smoker 26.4% 12.2% [16]*
Left ventricular hypertrophy 5.7% 9.9% [16]*
Atrial ﬁbrillation 4.6% 7.6% [16]*
Total cholesterol in mg/dl 247.2 (47.3) 257.3 (44.7) [40]†
HDL-cholesterol in mg/dl 49.6 (15.2) 62.4 (17.8) [40]†
Mean age at menopause‡ — 52 [59]
Alcohol consumption§ — 23.4% [16]*
Previous myocardial infarction 10.1% 4.9% [16]*
Previous angina pectoris 10.2% 9.8% [49]
Previous other CV events 26.1% 28.7% [16]*
Previous stroke 64.4% 56.1% [16]*
Previous TIA 22.3% 33.7% [16]*
Previous other CBV events 13.3% 10.2% [16]*
*Data for males and females as well as parameters not shown in the MOSES publication have been provided on request by the MOSES study team.
†Cholesterol values have not been recorded during the MOSES study, thus data from the German federal health survey 1998 were used.
‡During the simulation the mean age of menopause was used to simulate whether a female patient had already entered menopause.
§According to the Framingham algorithms moderate alcohol consumption has only a preventive effect in females.
SBP, systolic blood pressure; DBP, diastolic blood pressure;TIA, transient ischemic attack.
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Because of the fact that the model discriminates between
compliance and noncompliance, the costs for therapy-related
monitoring were included additionally.
For each event, country-speciﬁc direct health-care costs for
the ﬁrst year (after the occurrence of the event) as well as for the
subsequent years (second and following years after occurrence of
the event) were evaluated on the basis of published literature. If
more than one cost value was identiﬁed for the same event, a
mean value was calculated. The cost data used reﬂects a health-
care payer perspective.
All cost values retrieved from published literature were
inﬂated to 2007 values using the country-speciﬁc health-care cost
indexes (Belgium [62], Germany [63], Norway [64], Spain [65],
Sweden [66], and the UK [67]).
Because of a lack of published literature, the Norwegian event
costs have been estimated on the basis of Swedish event cost data
using a Norwegian study [68] on stroke costs as the transforma-
tion basis. According to the comparison of Swedish and Norwe-
gian costs for stroke care the Norwegian health-care costs are
around 6% higher than the Swedish health-care costs, hence the
Norwegian health-care costs are estimated using this transition
factor.
All costs were transferred to euros using the average exchange
rate of the year 2007 (January to November) provided by the
European Central Bank [69].
Analyses
Analyses were performed using patient cohorts of 1000 patients
and 1000 iterations (different starting numbers of the random
number generator) for each cohort using a 5-year treatment time
horizon in primary prevention and a 2.5-year treatment time
horizon in secondary prevention, simulating the treatment
follow-up effects over lifetime. The incremental cost-effectiveness
ratio (ICER) is shown as mean costs per QALY gained from a
health-care payer perspective.
A probabilistic sensitivity analysis was performed to show the
variability of results based on randomization (ﬁrst order) and
input parameter distributions (second order).
The inﬂuence of changes in single parameters was tested in
one-way sensitivity analyses that are shown as a tornado
diagram.
In the ﬁeld of primary prevention, this includes the discount-
ing of costs (0–10%) and effects (0–10%), the secondary preven-
tion of CV diseases (no RR reduction; RR risk reduction =
primary prevention), systolic blood pressure reduction (extreme
cases using the upper and lower conﬁdence intervals); the treat-
ment time horizon (1 year and 10 years), the utility reduction
caused by TIA (reduction was set to zero), the baseline utility
Table 5 Health utility weights used in the HEALTH model
Health state Males Females
Basis utility 0.7257 0.6850
Utility adaptation because of age* +X*
Utility reduction hypertension† -0.0407
Utility reduction MI or AP primary event -0.1156
Utility reduction MI or AP subsequent event -0.0578
Utility reduction stroke or TIA primary event -0.2743
Utility reduction stroke or TIA subsequent event -0.1372
*X = 0.2202 (20–29 years); 0.2104 (30–39); 0.1897 (40–49); 0.1624 (50–59); 0.1335 (60–69);
0.0967 (70–79).
†Applied to all patients.
MI, myocardial infarction;AP, angina pectoris;TIA, transient ischemic attack.
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according to age (minimum and maximum values), the variation
of health utility weights by 10% and the effect of excluding
patient compliance on ACEIs and ARBs (setting year 1 and year
4 compliance to 100% for both primary treatments).
Furthermore, the variations in the cost-effectiveness were
tested using different population characteristics that were
assumed to have a major inﬂuence on the basic risk for CV and
CBV events. Therefore, analyses were performed for males
(100%) and females (100%), different age groups and patients
with and without type 2 diabetes.
In the ﬁeld of secondary prevention, the one-way sensitivity
analyses focus on the discounting of costs (0–10%) and effects
(0–10%), the secondary prevention of CV diseases (no RR reduc-
tion; RR risk reduction = primary prevention), blood pressure
reduction beyond blood pressure reduction for CV events (reduc-
tion was set to zero); the treatment time horizon (1 year to 10
years), the utility reduction caused by TIA (reduction was set to
zero), the baseline utility according to age (minimum and
maximum values) the variation of health utility weights by
10%.
Furthermore, the variations in the cost-effectiveness were
tested using different population characteristics that were
assumed to have a major inﬂuence on the basic risk for CV and
CBV events. Therefore, analyses were performed for males
(100%) and females (100%), different age groups and patients
with and without type 2 diabetes.
The ICER scatter-plots as well as the tornado diagrams are
shown for those countries that represent the lowest and the
highest mean cost per QALY gained within a primary preven-
tion and a secondary prevention population, respectively. The
rationale for this procedure is that only four scatter-plots and
tornado diagrams have to be presented (instead of 16) and that
this procedure enables the extreme variations of the modeling
results to be presented by choosing the countries with the
extreme results (highest and the lowest mean ICER per QALY
gained).
Results
Primary Prevention
Within a primary prevention cohort of 1000 patients, simulating
a lifetime horizon (treatment time horizon = 5 years), eprosartan
therapy avoided on average 2.9 MIs, 2.3 AP cases, 2.6 strokes,
0.7 TIAs, and 4.9 CV/ CBV mortality cases more than enalapril.
The results of a primary prevention population in all countries
are shown in Figure 2.
The mean costs per QALY gained in the primary prevention
simulations, comparing eprosartan to enalapril, are shown in
Table 7 and range from €7918 in Spain to €24,036 in Germany,
simulating 1000 patients and 1000 iterations over a lifetime
horizon. The undiscounted modeling results are given in brack-
ets, to provide an estimate on the inﬂuence of the country-speciﬁc
discount rates applied.
Secondary Prevention
Within a secondary prevention cohort of 1000 patients, simulat-
ing a lifetime horizon (treatment time horizon = 2.5 years), epro-
sartan therapy avoided on average 4.8 MIs, 7.0 AP cases, 9.4
strokes, 18.1 TIAs and 1.6 CV/CBV mortality cases more than
nitrendipine. The results of a secondary prevention population in
all countries are shown in Figure 3.
The mean costs per QALY gained in the secondary prevention
simulations, comparing eprosartan to nitrendipine, are shown in
Table 8 and range from €-5767 in Belgium to €9136 in Germany,
simulating 1000 patients and 1000 iterations over a lifetime
horizon. The undiscounted modeling results are given in brack-
ets, to provide an estimate on the inﬂuence of the country-speciﬁc
discount rates applied.
Probabilistic Sensitivity Analyses
The incremental cost-effectiveness scatterplots for the extreme
scenarios in primary (Spain and Germany) and secondary
0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0
Fatal CV/ CBV
events
TIA
Stroke
Angina pectoris
Myocardial infarction
Events avoided by eprosartan simulating 1,000 patients over a lifetime horizon
Belgium Germany Norway Spain Sweden UK Average
Figure 2 Events additionally avoided by eprosartan compared to enalapril in 1000 patients simulating a lifetime horizon (primary prevention).
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prevention (Belgium and Germany) simulations are shown in
Figure 4.
Considering a willingness to pay threshold of €30,000 per
QALY gained the probability of eprosartan being cost-effective
compared to enalapril was 61.2% in Belgium, 55.9% inGermany,
69.5% in Norway, 76.6% in Spain, 72.3% in Sweden and 63.5%
in the UK, simulating a primary prevention population.
In secondary prevention, the probability that eprosartan is
cost-effective compared to nitrendipine was 100%, independent
of the country and considering €30,000 as the willingness to pay
threshold.
OneWay Sensitivity Analyses
The tornado diagrams for the primary prevention and the sec-
ondary prevention settings are shown in Figure 5.
In the primary prevention setting, the variables with the
greatest inﬂuence on the analysis results were the patients’ base-
line age, systolic blood pressure reduction, the cost and effect
discount rate, the patient’s sex and the baseline systolic blood
pressure. Considering the country simulation with the highest
mean incremental cost-effectiveness ratio (Germany) the varia-
tion of these parameters led to mean costs per QALY gained that
exceed the applied willingness to pay threshold of €30,000.
Setting patient compliance rates for years 1 and 4 to 100% for
both ACEI and ARB therapies also resulted in an ICER greater
than €30,000 per QALY gained in Germany (€33,210 per QALY
gained).
Because of the fact that the baseline age and the baseline
systolic blood pressure could be inﬂuenced by the physician’s
patient selection for eprosartan therapy the cutoff values for
cost-effectiveness have been investigated for all countries.
Starting from an age of 37 in Spain (ICER per QALY gained
= €28,488) and from an age of 52 in Germany (ICER per QALY
gained = €29,924) the therapy of eprosartan is cost-effective
compared to enalapril, whereas in younger patients the willing-
Table 7 Costs, utilities and cost per QALY gained comparing eprosartan to enalapril in primary prevention (1000 patients & 1000 iterations)
Country
Eprosartan Enalapril Incremental
ICER (€) per QALYCosts (€) Utilities Costs (€) Utilities Costs (€) Utilities
Belgium 6,277,551 10,359.0 5,629,136 10,322.7 648,415 36.3 17,863
(9,711,995) (15,181.2) (9,022,023) (15,123.6) (689,972) (57.6) (11,979)
Germany 7,041,011 9,182.6 6,267,037 9,150.4 773,974 32.2 24,036
(13,264,824) (15,431.2) (12,432,230) (15,370.5) (832,594) (60.7) (13,717)
Norway 8,123,926 8,456.1 7,566,432 8,415.8 557,494 40.3 13,834
(12,649,227) (12,247.0) (12,055,162) (12,183.7) (594,065) (63.3) (9,385)
Spain 4,969,228 8,270.8 4,593,935 8,223.4 375,293 47.4 7,918
(6,947,761) (11,122.5) (6,549,422) (11,054.9) (398,339) (67.6) (5,893)
Sweden 8,625,087 8,870.4 8,081,451 8,823.9 543,636 46.5 11,691
(12,071,172 (11,752.8) (11,499,298) (11,687.8) (571,874) (65.0) (8,798)
UK 5,490,508 8,708.6 4,894,846 8,672.2 595,662 36.4 16,364
(8,112,946) (12,221.0) (7,482,392) (12,167.2) (630,554) (53.8) (11,720)
ICER per QALY, Incremental cost-effectiveness ratio per QALY gained; cost and effects were discounted according to country-speciﬁc guidelines; (undiscounted modeling results are given in
brackets).
0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 16.0 18.0 20.0
Fatal CV/ CBV
events
TIA
Stroke
Angina pectoris
Myocardial infarction
Events avoided by eprosartan simulating 1,000 patients over a lifetime horizon
Belgium Germany Norway Spain Sweden UK Average
Figure 3 Events additionally avoided by eprosartan compared to nitrendipine in 1000 patients simulating a lifetime horizon (secondary prevention).
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ness to pay threshold is exceeded. The exclusion of the patient
compliance factor in Spain did not result in an ICER greater than
the willingness to pay threshold (€10,734 per QALY gained).
The cutoff values for the baseline systolic blood pressure are
164 mm Hg (ICER per QALY gained = €29,694) in Germany
whereas in Spain even patients within a mild systolic hyperten-
sion range (140–159 mmHg) showed excellent CE results
(<€20,000 per QALY gained).
Within a secondary prevention setting, the patient’s sex and
baseline age had the most signiﬁcant effect on cost-effectiveness
results. These results, however, were still below the willingness to
pay threshold of €30,000 even for the extreme case of Germany.
Discussion
Primary Prevention Setting
Simulating a health-care payer perspective over a lifetime
horizon, the mean ICER per QALY gained by eprosartan in
comparison to enalapril, was always below the assumed willing-
ness to pay threshold of €30,000, independent of the country
analyzed.
The highest costs per QALY gained have been observed simu-
lating a German health-care setting (€24,036) followed by
Belgium (€17,863), the UK (€16,364), Norway (€13,834),
Sweden (€11,691) and Spain (€7918).
These results were extensively tested by sensitivity analyses
that considered the analysis setting with the highest ICER per
QALY gained, the German health-care setting, had a strong
inﬂuence on the cost-effectiveness when applying a conserva-
tively chosen cost per QALY gained threshold of €30,000.
The ICER was most sensitive to variations of the mean age at
baseline, systolic blood pressure reduction, the cost and effect
discount rate, the patient’s sex, baseline blood pressure and
patient compliance.
The inﬂuence of age on the cost-effectiveness of antihyperten-
sives is well established [109]. Younger patients are in general at
lower risk of experiencing CV and CBV events than older ones,
thus a higher ICER is expected in younger patients from a health-
care payer perspective. Considering the worst-case scenario
(Germany) the cutoff age for cost-effectiveness, choosing a
threshold of €30,000, was determined at 52 years of age. In
younger patients the willingness to pay threshold was exceeded.
Considering the best-case scenario (Spain) the cutoff age for
cost-effectiveness was observed at 37 years of age. The cutoff
ages within all other countries have not been investigated, but are
expected to be located somewhere between the range of 37 and
52 years, observed in the two extreme scenarios.
In the model, systolic blood pressure reduction was used to
estimate the preventive effect of antihypertensive drugs on CV
and CBV events. The use of this approach has been conﬁrmed by
ﬁndings of recently conducted meta-analyses [6,7].
Modeling the extreme case using the upper 95% CI for enala-
pril and the lower 95% CI for eprosartan resulted in an ICER of
eprosartan that exceeded €30,000 compared to enalapril. This
extreme case of the 95% CIs, and so the lowest possible blood
pressure reduction difference between eprosartan and enalapril,
has to be regarded as a result that is statistically possible in
individual patients but not in a whole population, where a blood
pressure reduction near to the mean is to be expected. Neverthe-
less, this sensitivity analysis showed that the model is sensitive to
variations in systolic blood pressure reduction.
Discounting future health effects and future costs has had a
strong inﬂuence on the cost-effectiveness results. This is mainly
based on the fact that a lifetime horizon was simulated and as a
result most of the costs and health effects are to be expected in
the future, which makes the results more sensitive to discounting
in contrast to simulations focusing to a shorter observation
period.
The inﬂuence of sex on the cost-effectiveness of antihyperten-
sive treatments has already been investigated by a Scandinavian
CE analysis [109]. In females the ICER per QALY gained was
higher than in males. This variation is based mainly on the lower
CV and CBV risk of females in comparison to males. This is
conﬁrmed with the general rule for preventive therapies (e.g.,
antihypertensive therapy) that says the lower the CV and CBV
base risk, the lower the effect of a preventive therapy.
Sensitivity analyses varying the systolic baseline blood pres-
sure values have shown a higher ICER per QALY gained the lower
the baseline systolic blood pressure was. Considering the worst-
case scenario (Germany) the cutoff value for cost-effectivenesswas
a baseline systolic blood pressure of 164 mm Hg. Starting from
this blood pressure level cost-effectiveness was also achieved for a
German health-care setting. In Spain themodeling resultswere not
sensitive to the baseline systolic blood pressure.
The efﬁcacy data used in the HEALTH model are mainly
based on the Sega et al. study [10] that found a signiﬁcant dif-
ference in systolic blood pressure reduction when comparing
eprosartan to enalapril. The time horizon of this trial (10 weeks)
does not deliver valid data for a 5-year treatment time horizon.
Nevertheless, another study with a treatment duration of 2 years
showed that eprosartan would keep the initial blood pressure
Table 8 Costs, utilities and cost per QALY gained comparing eprosartan to nitrendipine in secondary prevention (1000 patients & 1000 iterations)
Country
Eprosartan Nitrendipine Incremental
ICER (€) per QALYCosts (€) Utilities Costs (€) Utilities Costs (€) Utilities
Belgium 17,867,996 3,244.3 18,081,950 3,207.2 -213,954 37.1 -5,767
(21,388,173) (3,986.2) (21,587,048) (3,943.3) (-198,875) (42.9) (-4,635)
Germany 28,967,343 3,041.8 28,643,914 3,006.4 323,429 35.4 9,136
(36,813,615) (4,037.1) (36,440,516) (3,993.7) (373,099) (43.4) (8,597)
Norway 34,993,752 3,247.1 34,930,873* 3,210.0 62,879 37.1 1,695
(42,658,337) (4,114.9) (42,555,073) (4,071.0) (103,264) (43.9) (2,352)
Spain 15,015,775 3,084.8 15,089,497 3,048.9 -73,722 35.9 -2,054
(19,155,946) (4,121.5) (19,215,025) (4,077.4) (-59,079) (44.1) (-1,340)
Sweden 36,318,567 3,404.9 36,283,665* 3,366.4 34,902 38.5 907
(42,422,941) (4,085.6) (42,352,811) (4,041.8) (70,130) (43.8) (1,601)
UK 19,313,238 3,292.4 19,087,933* 3,254.9 225,305 37.5 6,008
(23,163,526) (4,057.4) (22,918,206) (4,013.9) (245,320) (43.5) (5,640)
*Nitrendipine is not licensed in Norway, Sweden and the UK, hence the costs of amlodipine (5 mg) were used as model input.
ICER per QALY, Incremental cost-effectiveness ratio per QALY gained; cost and effects were discounted according to country-speciﬁc guidelines; (undiscounted modeling results are given in
brackets).
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reduction at the titration end point (week 15) over the whole
study period (2 years) [110]. According to this trial it is assumed
that both eprosartan and enalapril will be able to maintain the
initial blood pressure reduction over a long time horizon.
Changes in systolic blood pressure reduction over this time
horizon are taken into account by including the patient compli-
ance that decreases continuously in the course of time [27]. Thus,
the mean systolic blood pressure in each treatment arm rises
continuously because of the fact that noncompliant patients
were considered to have no blood pressure reduction. To test the
inﬂuence of the treatment time horizon on the cost-effectiveness
of eprosartan, sensitivity analyses assuming shorter and longer
treatment time horizons were performed (1 year and 10 years)
without showing a major impact on the cost-effectiveness of
eprosartan.
The model uses the DDD costs of eprosartan and enalapril
instead of the drug dose distribution observed in the Sega et al.
trial. The rationale for this was that the twice-daily 400 mg
eprosartan dose, as given to some patients within the underlying
efﬁcacy trial, is not available in all the countries investigated. If it
were possible to reﬂect the drug doses used in the Sega study, a
mean 683 mg daily dose of eprosartan (instead of 600 mg) would
have to be compared to a mean 32.6 mg daily dose of enalapril
(instead of 10 mg).
Thus, in general, using the DDD in the primary prevention
setting is likely to underestimate the drug costs of enalapril,
leading to a conservative estimation of the treatment cost of the
comparators.
Secondary Prevention Setting
Simulating a health-care payer perspective over a lifetime horizon
the mean ICERs per QALY gained by eprosartan in comparison
to nitrendipine were always below the assumed willingness to
pay threshold of €30,000, independent of the country analysed.
The highest costs per QALY gained have been observed simu-
lating a German health-care setting (€9136) followed by the UK
(€6008), Norway (€1695), Sweden (€907), Spain (€-2054), and
Belgium (€-5767).
These results were extensively tested by sensitivity analyses.
The ICER was most sensitive with respect to the baseline age as
well as the sex, without changing the cost-effectiveness results
fundamentally (all results remained below the assumed willing-
ness to pay threshold of €30,000 per QALY gained). Both of
these aspects (inﬂuence of age and inﬂuence of sex) have already
been discussed in the previous chapter (primary prevention
discussion).
The outcomes of the secondary prevention simulations are
further strengthened by the results of the probabilistic sensitivity
analyses that have shown convincing results with a probability of
100% that eprosartan is a cost-effective treatment strategy com-
pared to nitrendipine regardless of the country analysed.
One limitation of the secondary prevention model, which is
mainly based on the outcomes of the MOSES study, is the uncer-
tainty concerning the mortality prediction in this speciﬁc popu-
lation with stroke and concomitant hypertension. Therefore two
different settings were analysed. In the ﬁrst setting (base case) the
probability of death was simulated by the Framingham mortality
algorithms, whereas in the sensitivity analysis the MOSES mor-
tality was applied. This probability of death based on the
MOSES study was lower than the probability of death predicted
by the Framingham algorithms. The mean 1-year period from the
occurrence of the CBV to the patient’s recruitment in the MOSES
study was identiﬁed as the main reason for this difference,
because mortality (especially mortality because of stroke) is
highest in the ﬁrst year after the event, according to published
studies [24,25]. Simulating both approaches the Framingham
mortality was considered to be more realistic and was therefore
used for the base case analyses. Although there is the above
mentioned uncertainty concerning the mortality prediction in the
secondary prevention population, the impact of using the
MOSES or the Framingham prediction on the cost per QALY
gained is limited, as shown in the one-way sensitivity analyses.
Another limitation of the simulation was that we applied a
risk reduction beyond blood pressure reduction for both CV and
CBV events. Looking at the results of the MOSES study [16]
there was a signiﬁcant difference in the reduction of CBV and
ﬁrst CV events (P = 0.026 and P = 0.03) between the treatment
groups, whereas the difference in reducing the recurrent CV
events was only of borderline signiﬁcance (P = 0.061). A further
limitation of the secondary prevention analyses is that costs for
nitrendipine were not available for Sweden, Norway and the
United Kingdom. As a proxy, the local cost for amlodipine was
used in each setting. This assumption may have improved cost-
effectiveness claims for eprosartan if nitrendipine would be
cheaper than amlodipine in these settings.
In view of the sizable difference in the number of CV events
comparing eprosartan (4.95 CV events per 100 patient years)
and nitrendipine (6.62 events per 100 patient years) we decided
to simulate the CV risk reduction of 25% in the base case setting,
although the statistical evidence only supports this procedure
with respect to the ﬁrst CV events, rather than with respect to
recurrent CV events.
To investigate the impact of including the CV event risk
reduction one way-sensitivity analyses have been performed that
excluded the risk reduction for CV events beyond blood pressure
reduction. The sensitivity analyses results show that the impact
of excluding the CV event risk reduction had only a minor
impact on the results without inﬂuencing the cost-effectiveness of
eprosartan fundamentally.
We did not assess the beneﬁts of ﬁxed-dose combination
therapies for hypertension in this analysis. A recent literature
review has suggested that combination therapy may result in
superior blood pressure reductions compared to monotherapy in
hypertension [111]. Furthermore, recent clinical trials have sug-
gested beneﬁts for ﬁxed-dose combination with an ARB and a
calcium channel blocker because of superior blood pressure
reduction and better tolerability than either agent alone [112].
Nevertheless, the combination of telmisartan and ramipril in the
recent ONTARGET trial was not shown to improve survival or
reduce renal events in patients with mild hypertension [113], and
guidelines for the treatment of hypertension in the United
Kingdom stipulate that combination therapy should be used only
when patients fail to reach blood pressure targets on mono-
therapy [114]. Given conﬂicting evidence on the beneﬁts of com-
bination therapy for primary prevention, our ﬁndings that
eprosartan as monotherapy is a cost-effective alternative to
enalapril are relevant.
Conclusion
The results of the HEALTH model simulations in Belgium,
Germany, Norway, Spain, Sweden, and the UK provide evidence
that eprosartan is a cost-effective treatment strategy compared to
enalapril in primary prevention and to nitrendipine in secondary
prevention.
The cost-effectiveness in primary prevention is especially sen-
sitive to changes in central patient characteristics, such as age and
baseline systolic blood pressure. These patient characteristics are
the two main factors to be considered for the prescription of
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eprosartan in primary prevention. Considering the country with
the highest cost per QALY gained (Germany), starting from
the age of 52 years and a baseline systolic blood pressure
164 mm Hg, eprosartan becomes a cost-effective treatment
option compared to enalapril, although the generic price level
leads to a sizable difference in the drug therapy costs, and the
exclusion of patient compliance with treatment (both ACEI and
ARB) did not result in cost-effectiveness in Germany. In all other
countries analysed cost-effectiveness is also observed in younger
patients and in patients with a lower baseline systolic blood
pressure. Nevertheless, the focusing on older patients (50 years
of age) with a higher systolic blood pressure (160 mm Hg) was
identiﬁed as reasonable patient selection criteria to ensure a
cost-effective application of eprosartan within a primary preven-
tion setting.
The cost-effectiveness outcomes show considerable evidence
for the cost-effectiveness of eprosartan compared to nitrendipine
within a secondary prevention population in all countries inves-
tigated, without any limitation related to the patient selection.
Supporting information for this article can be found at: http://
www.ispor.org/publications/value/ViHsupplementary.asp
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